substantially more cases with Xpert (n ¼ 1809) than with phenotypic DST (n ¼ 1592). Among strains with discordant results, rpoB sequencing revealed only one false-resistant result (new TB case) with Xpert and 7.7% (8/104) of RMP-resistant cases missed with Xpert against 3.8% (4/14) by phenotypic DST. This difference was not significant.
C O N C L U S I O N S :
This survey provides the first representative data for Pakistan on its MDR-TB burden. The Xpert assay had nearly 100% specificity, even in a low MDR-TB prevalence setting. The use of this assay greatly simplifies survey logistics, making it a feasible option for survey implementation, especially in resource-constrained settings. K E Y W O R D S : tuberculosis; drug resistance; surveillance; MDR-TB; rifampicin DRUG-RESISTANT TUBERCULOSIS (TB) represents a major threat to TB control worldwide. Knowing its magnitude and monitoring trends over time are crucial to designing effective interventions to prevent the development of drug resistance and control its spread. Surveillance for drug resistance is therefore a critical component of any TB control programme. 1 Among the most important challenges hindering the implementation of drug resistance surveys is the lack of laboratory capacity for culture and drug susceptibility testing (DST) and the need to ensure rapid and effective transportation of sputum specimens to the reference laboratory for testing. 2 If these problems could be overcome through the use of less demanding laboratory technologies for the identification of drug resistance, more regular assessments of levels of drug resistance would be possible, even in countries with limited laboratory infrastructure and suboptimal surveillance systems. 3 Molecular technologies endorsed by the World Health Organization (WHO) 4, 5 are increasingly being incorporated into drug resistance surveys to simplify logistics, facilitate sample transportation, diminish laboratory workload and reduce costs. 3, 6 The use of the Xpert w MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) for surveillance purposes has been recommended by the WHO in its latest guidelines. 1 Pakistan is a low-to-middle-income country with a high TB burden 6, 7 and low human immunodeficiency virus (HIV) prevalence. The DOTS strategy promoted by the WHO to prevent and control TB has been fully implemented in the public health sector of the country since 2005, and has also been expanded to the private health sector. Sputum smear microscopy is used as an initial screening test for TB diagnosis. Since 2012, patients newly diagnosed with TB have received 6-month short-course treatment, 8.9 while those diagnosed with drug-resistant TB receive a longer secondline regimen. 10 The Xpert assay was introduced into Pakistan in 2011 for the rapid detection of rifampicin (RMP) resistance in patients at risk of drug-resistant TB. 5, [9] [10] [11] In Pakistan, knowledge of the extent of drug resistance in new TB cases is limited. The level of multidrug-resistant TB (MDR-TB, defined as resistance to at least both RMP and isoniazid [INH] ) in new cases was reported as 1.8% in a study conducted in convenience selected sites in 2005. 12 Here we present the results of the first national anti-tuberculosis drug resistance survey conducted in Pakistan in 2012-2013. Xpert was used in parallel with conventional phenotypic DST on Löwenstein-Jensen (LJ) medium to assess its feasibility, effectiveness and usefulness in the context of a survey.
STUDY POPULATION AND METHODS

Study design
The study was cross-sectional, targeting all consecutively notified new and previously treated smearpositive TB patients in 40 clusters. Clusters were selected using a probability proportional to size approach based on the numbers of sputum smearpositive pulmonary TB (PTB) cases notified to the National TB Control Programme (NTP) in the previous year. The sampling frame comprised all 1122 microscopy centres functioning nationwide in primary, secondary, tertiary and specialised TB health care facilities, including in the private sector. However, 24 centres located in the Federally Administered Tribal Area (FATA) region were excluded from the sampling frame due to security reasons.
Based on the number of new smear-positive patients recorded by the NTP in 2008 (n ¼ 101 887) and an anticipated prevalence of MDR-TB of 1.8% among new cases, 12 a sample size of 1600 new sputum smear-positive PTB cases was determined, with the desired precision of 1% at the 95% confidence level. This takes into account a design effect of 2 due to clustering of patients, and an expected 20% losses for reasons such as insufficient or contaminated samples. There was no separate sample size calculation for previously treated smearpositive PTB cases due to the small number notified annually, 1 which in 2008 accounted for 7.4% of all notified smear-positive PTB cases. Sputum smearpositive PTB cases of any age registered at the study sites as new or previously treated (treatment of at least 1 month duration) during the study period were eligible for inclusion.
The enrolment period across the clusters was staggered to avoid overload at the laboratory. Patient enrolment began in April 2012 and was completed in September 2013. A set of variables were collected for each patient through a questionnaire administered at the time of enrolment, including sex, age, place of residence, treatment history (new/previously treated case), education and smoking status. Medical records were reviewed to confirm the reliability of the information gathered.
Ethical clearance for the survey was obtained from the Ethical Review Committee of The Pakistan Medical Research Council, Islamabad. Only patients diagnosed with RMP-resistant TB were referred to established treatment sites for appropriate treatment.
Laboratory methods
Two sputum specimens (spot and morning samples) were collected from eligible patients, where possible. Specimens were transported from the cluster site by a courier service maintaining a cold chain, with a target of reaching the National TB Reference Laboratory (NRL) in Islamabad within 72 h. When two specimens were available, Xpert was performed on the spot specimen and the morning specimen was processed for culture. When only a single specimen was available, both Xpert and culture were performed on aliquots from the same specimen. Xpert was performed directly on sputum according to the manufacturer's instructions. 11 The specimen for culture was decontaminated in 4% sodium hydroxide, and then inoculated without centrifugation on two slopes of Kudoh modified-acid Ogawa medium. 13 Slopes were incubated at 378C and monitored weekly for growth for up to 8 weeks. For positive cultures, identification of Mycobacterium tuberculosis was based on phenotypic appearance of colonies, acid fastness on Ziehl-Neelsen stained smears and confirmation of M. tuberculosis complex by detection of MPB64 Ag using the TBc ID kit (BD, Franklin Lakes, NJ, USA). All strains were also tested for paranitrobenzoic acid at 500 lg/ml sensitivity. All pure M. tuberculosis isolates were tested for resistance using the LJ proportion method for first-line drugs at the following concentrations: 40 lg/ml for RMP, 0.2 lg/ ml for INH, 2.0 lg/ml for ethambutol (EMB) and 4.0 lg/ml for streptomycin (SM). 14 All MDR-TB isolates were further tested for resistance against second-line drug concentrations of 2.0 lg/ml for ofloxacin (OFX), 30.0 lg/ml for kanamycin (KM), 40.0 lg/ml for amikacin (AMK) and 40.0 lg/ml for capreomycin (CPM). 15 For quality control, strain H37Rv and two different MDR-TB reference strains were tested with each batch of DST at the NRL. When RMP results at the NRL were discordant between two testing methods, phenotypic DST was repeated at the NRL and Xpert was performed on the culture isolates at 10 À4 dilution (McFarland 1).
For external quality assurance, all M. tuberculosis strains reported as RMP-resistant on LJ DST and/or on Xpert were sent to the Supranational TB Reference Laboratory (SRL) in Antwerp, Belgium, for confirmation, even in the case of concordant results (Table  1 ). An almost equal number of randomly selected RMP-susceptible strains was retested at the SRL. At the SRL, DST on LJ media and sequencing of the rpoB gene was performed systematically on these strains. Molecular identification of those strains found not to represent pure M. tuberculosis was also performed.
Final decision and interpretation of laboratory results
Strains considered RMP-resistant were 1) any strain found to be resistant to RMP on LJ DST conducted at the SRL; 2) any strain found to be susceptible to RMP on LJ DST conducted at the SRL, but carrying a mutation in the rpoB gene known to confer resistance; and 3) any specimen resistant to RMP on Xpert, but for which results from LJ DST or sequencing were not available. The result of LJ DST performed at the SRL overruled the results of the DST conducted at the NRL. Strains found to be susceptible to RMP on LJ DST and/or on Xpert that were not retested at the SRL were considered susceptible.
Statistical analysis
The data were entered into purposely designed EpiData Entry 3.1 software (EpiData Association, Odense, Denmark) and analysed using Stata statistical software (Release 13.0, Stata Corporation, College Station, TX, USA). For quality control, around 20% of the data were double-entered and any discrepancies were resolved by reviewing the source documents.
Proportions of MDR-TB and RMP resistance were computed using logistic regression with robust standard errors to account for clustering with multiple imputation of missing values. The analysis was performed both with and without sample weights (target cluster size divided by number enrolled in cluster) to account for under and over enrolment, and the results compared. Due to minimal difference between the results, sample weights were not used in the final analysis. The analysis was also performed both with and without multiple imputation of missing values, and the results were compared.
RESULTS
A total of 1984 PTB cases were enrolled, including 1695 new, 277 previously treated and 12 unclassified cases based on treatment history. The final analysis was performed among 1972 cases, excluding those with missing treatment history (Figure) . Of the 1972 eligible patients enrolled, 54.7% (n ¼ 1078) were male. The median age was 33 years (males 37 years, females 30 years), 2.4% (n ¼ 47) of whom were aged ,15 years and 9.5% (n ¼ 188) .65 years. Among MDR-TB cases (n ¼ 96), 45.8% (n ¼ 44) were male and the median age was 30 years (males 31 years, females 30 years).
Conventional culture and drug susceptibility testing performance Culture was performed on 1917 (97.2%) samples (Table 2) ; 60% of the samples reached the NRL within 72 h. The proportion of samples with losses due to leakages, contamination and negative cultures was 11.6% (n ¼ 136) among those received within 72 h, compared to 24.6% (n ¼ 198) among those received after 72 h. Phenotypic DST on LJ media was performed on M. tuberculosis isolates from 1592 cases (Tables 1 and 3) .
RMP resistance by LJ was reported in 106 cases in the NRL, six of which were reported susceptible by the SRL (Table 1 ). This was confirmed by retesting at the NRL. The reason for the error in the initial result at the NRL could not be determined.
Xpert MTB/RIF assay performance Of 1972 cases enrolled, 1914 (97.1%) were tested using Xpert. Results were not obtained in 28 (1.3%) cases due to errors, M. tuberculosis was not detected 
DISCUSSION
This is the first nationwide survey of MDR-TB in Pakistan and the first survey, to our knowledge, in which conventional phenotypic DST and testing with Xpert were performed in parallel. The proportion of patients for whom a phenotypic DST result was not available, either due to contamination, negative culture or sample loss during transportation, was just slightly less than the 20% factored into the sample size calculation. This proportion is similar to 16 or slightly higher than that reported by other large nationwide drug resistance surveys. [17] [18] [19] [20] [21] The slightly higher proportion of sample losses in our study could be explained by the fact that only a single specimen was processed for culture, preservative was not used and about 40% of the specimens were exposed to high temperatures during transportation for more than 3 days. These factors had little effect on Xpert, and we were able to obtain a substantially higher proportion of valid Xpert results (91.7%) than for phenotypic DST (80.7%). This highlights the usefulness of molecular technologies for the surveillance of drug-resistant TB. The performance of Xpert in surveys can be further improved by decentralising the initial testing to cluster level. However, rapid specimen transport would still be required for the RMP-resistant samples, which should undergo DST for other drugs, and particularly second-line drugs. With this approach, there would be only a slight additional workload for the NRL, limited to patients who would need to undergo further DST and treatment for drug-resistant TB. The MDR-TB rate of 3.7% among new cases and 18.1% among previously treated TB cases detected in this survey is in line with those reported by other countries in the region. 6 Based on these proportions, the total number of MDR-TB cases estimated among PTB cases notified in 2014 was 9000 (uncertainty interval 6100-12 000) among new and 2900 (2100-3700) among previously treated cases, for a total of around 11 900 cases, compared to only 3243 RMPresistant TB cases notified to the NTP. 6 In Pakistan, targeted screening using Xpert is recommended for patients at risk of MDR-TB (contacts, failures and relapses). 9 However, given that more than 75% of the MDR-TB burden is among new TB cases, the algorithm for screening of cases for drug-resistant TB needs to be reviewed in parallel with a scale-up of programmatic management of drug-resistant TB. The proportion of XDR-TB among MDR-TB cases reported in our study is 3.1%, and close monitoring for future trends will be required.
Among RMP-resistant cases, a high proportion of both new (90.9%) and previously treated (91.5%) cases were MDR-TB. RMP resistance can therefore be considered a good proxy indicator of MDR-TB in Pakistan. Among all TB cases, the proportion of INH resistance without concurrent RMP resistance was similar in new (8.3%) and previously treated (7.1%) TB patients. However, further studies are needed to determine the clinical relevance of INH resistance, its impact on treatment outcomes and the need for any change in treatment regimen.
In our survey, all RMP-resistant cases reported either on LJ DST or Xpert were retested. As a result of the use of sequencing along with the LJ DST results at the SRL for guiding the final decision, discordances between Xpert and LJ DST were resolved and the actual number of false-susceptible RMP results on LJ DST (n ¼ 4) and Xpert (n ¼ 8) could be confirmed. Xpert has been reported as having 100% sensitivity in detecting RMP resistance in a few studies conducted on a smaller number of samples. 22, 23 Our survey supports findings from other studies of lower sensitivity for Xpert in detecting RMP resistance, but not lower specificity. [24] [25] [26] In our study, compared to the composite standard based on an RMP-resistant result on one or both of the two testing methods (DST and rpoB sequencing), the sensitivity of phenotypic DST (96.2%) was greater than that of Xpert (92.3%), which is attributed to use of slow, more sensitive solid DST. Lower Xpert specificity has been reported in studies using rapid phenotypic DST as the reference standard, as these tend to miss a sizeable proportion of difficult to detect RMP resistance. 27, 28 In our survey, after resolving discordant results, only one truly false RMP result remained for Xpert, and this was due to a silent mutation (in 525Thr). Xpert specificity was thus close to 100%, which highlights the fact that false results are very rare and certainly not dependent on prevalence.
A small number of RMP-resistant cases due to mutation outside the core region are missed by current molecular techniques. A recent report from Swaziland has raised questions as to the usefulness of Xpert, 29 as 30% of RMP-resistant strains studied (although small in absolute number) were carrying an rpoB mutation not covered by the assay. In our survey, only 7.7% (8/104) of the RMP-resistant strains were missed, and no significant difference was reported in the proportions of RMP-resistant cases determined using phenotypic DST compared to Xpert. Nonetheless, for clinical management, any RMP-susceptible result in a TB case with a high suspicion of drug resistance should be further investigated using phenotypic DST or sequencing.
As molecular techniques are rolled out and both phenotypic and molecular techniques are used in parallel, increasingly more laboratory-based diagnostic dilemmas are expected to be encountered in the clinical management of patients. In our survey, as recommended by the WHO, 11 these discordances were resolved by sequencing. However, in routine clinical practice this will not be possible in many resource-poor, high disease burden settings. Our findings indicate that technical false-resistant results on Xpert are very rare. Although other types of errors do occur, as with any test, they can be resolved by repeating the test with another specimen. If performed at the same laboratory, the procedure can still be completed within 1 day. Only in a few areas where clonal spread of a particular silent mutation has been reported will sequencing be needed for confirmation. 30 A limitation of our study was that sputum samples with valid results on Xpert only could not be retested at the SRL. Similarly, in the case of discordant results, Xpert testing was repeated on culture isolates rather than on sputum samples.
CONCLUSIONS
This survey provides the first representative data for Pakistan on the proportion of new and previously treated TB patients with drug-resistant TB. This is the first national survey to use Xpert and phenotypic DST in parallel. Compared to phenotypic DST, the use of Xpert substantially reduced loss of eligible patients from the survey. It performed equally well in both new and retreatment cases and RMP resistance detected was highly reliable. Given the many advantages of speed, safety, decentralisation, logistics and lower costs compared to a culture/DST network, use of Xpert is a feasible option for implementing surveys and scaling up programmatic management of drugresistant TB, especially in resource-constrained settings. 
R E S U M E C O N T E X T E
R E S U M E N M A R C O D E R E F E R E N C I A:
La primera encuesta nacional sobre la tuberculosis (TB) farmacorresistente en Pakistá n, un país donde la carga de morbilidad por TB es alta y la carga que corresponde al virus de la inmunodeficiencia humana es baja. O B J E T I V O: Determinar la proporción de pacientes que albergan una TB multidrogorresistente (TB-MDR) y comparar el rendimiento diagnóstico de la prueba Xpert w MTB/RIF con el rendimiento de las pruebas fenotípicas clá sicas de sensibilidad a los medicamentos (DST).
M É T O D O S:
En un muestreo por conglomerados de 40 unidades se recogieron muestras de esputo de 1972 pacientes consecutivos con diagnóstico de TB pulmonar. Se practicaron las DST en paralelo con la prueba Xpert. R E S U LTA D O S: La proporción de pacientes con TB-MDR fue 3,7% (IC95% 2,5 a 5,0) en los casos nuevos y 18,1% (IC95% 13,0 a 23,4) en los casos anteriormente tratados. Los resultados vá lidos para la rifampicina (RMP) fueron mucho má s frecuentes con la prueba Xpert (n ¼ 1809) que con la DST fenotípica (n ¼ 1592). En las cepas con resultados discordantes, la secuenciación del gen rpoB reveló solo un resultado falso de resistencia con la prueba Xpert (un caso nuevo de TB); con esta prueba se pasó por alto un 7,7% de casos resistencia a RMP (8/104) comparado con un 3,8% en la DST fenotípica (4/104). Esta diferencia no fue estadísticamente significativa. C O N C L U S I O N E S: La presente encuesta aporta los primeros datos representativos sobre la carga de morbilidad por TB-MDR en Pakistá n. La prueba Xpert ofreció una especificidad cercana a 100% en un entorno con baja prevalencia de TB-MDR. La utilización de esta prueba simplifica en gran medida los aspectos operativos de la encuesta y convierte la prueba Xpert en una opción factible durante la ejecución de las encuestas, sobre todo en los entornos con limitaciones.
